RNS Number : 0994E

Omega Diagnostics Group PLC

26 October 2022


("Omega" or the "Company" or the "Group")

AGM Statement and Notice of Results

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, will hold i ts Annual General Meeting (AGM) today at 11.00am at Poets House, St Mary's Street, Ely, CB7 4EY.

The Company also announces that it has signed a heads of terms partnership agreement with a microbiome test provider, to develop a unique reporting tool for Omega which will broaden the Company's offering in line with its stated strategy.

Ahead of the meeting, Simon Douglas, Chairman of the Company, makes the following statement:

"After making the strategic decision to re-align the Group and dispose of the loss-making CD4 business in Alva, we are now exclusively focused on the profitable and cash generative Health and Nutrition business. We work with healthcare practitioners and patients directly, helping empower them to make even better-informed health decisions by putting personalised nutrition at the heart of global healthcare.

"As previously indicated, H1 revenues are expected to be softer than the prior period, down 18% to GBP3.4m, although full year expectations remain unchanged. Our UK sales team has performed well, signing up over 100 new UK practitioners resulting in CNS Lab sales increasing by 68% on the same period last year. We have also contracted new business partners in several new territories in which Omega has not historically operated, which is expected to drive future growth. FoodPrint(R) revenues are down 24%, although, as announced previously, this is primarily due to product re-registrations taking place following a substantial technical product change in May 2022. This regulatory change has impacted customer order profiles, particularly those of our larger distributors in North America and the Middle East. Food Detective(R) sales were broadly flat, although after a two-year hiatus, the Group's largest partner in China has now re-commenced ordering for delivery in H2. Our cash balance currently stands at GBP2.5million.

"We can confirm that Omega has now submitted comments to the World Health Organisation (WHO) on the draft Performance Evaluation report for the VISITECT(R) CD4 Advanced Disease Rapid test clinical study undertaken in Kenya , comfortably ahead of the required deadline, and now await further feedback from the agency. Following the outcome of this process we expect the WHO to publish their Prequalification Report shortly and remain confident that the Group will subsequently receive the full deferred consideration of GBP4.0m in the near term.

"As previously announced, the Group continues to be in dispute with the Department of Health and Social Care (DHSC) regarding the potential repayment of a pre-production payment of GBP2.5 million. The Board has agreed in principle to mediation with DHSC, although the timing for mediation is not yet confirmed.

"In terms of today's partnership agreement announcement, Omega is seeking to commercialise microbiome testing into its existing sales channels in order to provide a more comprehensive gut health assessment. Omega will work in partnership with the microbiome test provider to develop and commercialise a bespoke report for Omega, utilising the partner's proprietary software and Omega's sales channel.

"The Board remains confident in delivering full-year results in line with current market expectations and continues to believe there are substantial growth opportunities to come from the Health and Nutrition business. We look forward to updating shareholders in more detail at our interim results next month."

The Company intends to announce its interim results for the six months to 30 September 2022 on 24 November 2022.


 Omega Diagnostics Group PLC                                            www.omegadx.com 
 Jag Grewal, Chief Executive Officer                                    via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 finnCap Ltd                                                         Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore (Corporate 
 Alice Lane/Charlotte Sutcliffe 
 Walbrook PR Limited                         Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus / Sam Allen / Lianne                 Mob: 07980 541 893 / 07502 558 258 / 
  Applegarth                                                              07584 391 303 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

October 26, 2022 02:00 ET (06:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Omega Diagnostics Charts.